Prolonged treatment of an immunocompromised child with oseltamivir and zanamivir for A(H1N1)pdm09 virus infection led to the emergence of viruses carrying H275Y and/or E119G in the neuraminidase. When phenotypically evaluated by neuraminidase inhibition, the dual H275Y-E119G substitution caused highly reduced inhibition by four neuraminidase inhibitors including oseltamivir, zanamivir, peramivir and laninamivir.
INTRODUCTION
Neuraminidase (NA) inhibitors (NAIs) are vital for treating influenza infections among immunocompromised patients at high risk for influenza-associated complications and mortality.
Because currently circulating influenza viruses are resistant to M2 blockers, NAIs are the only effective FDA-approved drugs for treating influenza. The NAIs, orally administered oseltamivir and inhaled zanamivir, are licensed in most countries, while intravenous peramivir (1) is approved in the USA, Japan, South Korea, China, and inhaled laninamivir (2) in Japan. Intravenous (IV) zanamivir is undergoing evaluation for treatment of hospitalized patients with severe influenza (3) . Use of NAIs in immunocompromised patients who often have sustained viral replication is associated with emergence of drug resistance resulting from subtype-specific neuraminidase (NA) mutations (4) .
The H275Y substitution in the N1 NA is the most commonly observed change associated with resistance to oseltamivir and peramivir, and can emerge and persist following oseltamivir treatment in immunocompromised patients infected with influenza A(H1N1)pdm09 (5) . Use of zanamivir in patients infected with H275Y viruses is associated with reduced viral shedding and provides an alternative treatment (6) . Resistance to zanamivir has rarely been detected in clinical settings, and was first reported in an influenza B virus with R152K substitution, isolated from an immunocompromised patient (7). The emergence of I223R has been reported in A(H1N1)pdm09 viruses infecting immunocompromised patients, often in combination with or after the H275Y substitution has been detected (8) and results in reduced susceptibility to zanamivir. The variant has emerged after sequential oseltamivir and zanamivir treatment. By itself, I223R causes minimal effects on zanamivir susceptibility, but synergizes with H275Y to produce a greater effect. An I223R-H275Y double mutant exhibited ∼20-fold and ∼10-fold increases in zanamivir IC50,compared to the wild type virus and the H275Y mutant, respectively (8) .
We report the emergence of an influenza A(H1N1)pdm09 virus carrying a newly described substitution in the NA from an immunocompromised infant following prolonged zanamivir treatment. 
METHODS

Patient Information
The patient was an 8- A c c e p t e d M a n u s c r i p t 5 transplantation (day -10). Additional clinical specimens were submitted to CDC for evaluation after this specimen was fully characterized.
Virus Characterization
The CLIA-certified CDC pyrosequencing assay was used on the day -10 specimen to detect amino acid substitutions at the NA residues H275, I223, N295 and D199, and was performed on the PyroMark PSQ96™ MA platform (Qiagen, Valencia, CA). A pyrosequencing assay targeting residue E119 was specifically designed for this study (Supplemental Table S1 ). Sanger sequencing of NA genes was performed using standard procedures, and NA sequence data was deposited to the Global Initiative on Sharing All Influenza Data (GISAID), under the accession number EPI531845.
Virus propagation was performed in
Quantitative PCR analysis of respiratory specimens was performed as previously described (9) .
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RESULTS
The respiratory specimen submitted to CDC was obtained 10 days pre-transplantation (-10), after 47 days of zanamivir treatment and was tested with pyrosequencing for markers of NAI resistance (Table 1 ). The proportion of H275Y in the virus quasi-species was 23%, which was ~2-fold above the limit of detection in the pyrosequencing assay (cutoff 10%). The H275Y substitution is a marker of resistance to oseltamivir and peramivir. No amino acid changes were detected at residue I223, N295, or D199.
The virus isolate from this specimen (passage C1) was tested by NI assay (Table 2 ) and showed slightly reduced inhibition by oseltamivir (7-fold increase in IC50) and highly reduced inhibition by zanamivir (~1300-fold), peramivir (~170-fold) and laninamivir (~330-fold), compared to the wildtype reference virus, A/California/12/2012 (H1N1)pdm09. Notably, pyrosequencing of this isolate (C1) revealed only one NA virus variant, H275Y (5%) and no variants with the other 3 markers. To identify molecular changes responsible for the unusual NI assay profile, virus isolate (C1) was subjected to
Sanger sequencing and the E119G substitution was detected.
New primers were designed to extend the pyrosequencing assay to residue E119 (Supplemental Table S1 ). Using this assay, the E119G was detected in both the clinical specimen and virus isolate Additional clinical specimens (n=19) collected from the patient from day -64 to day +45, relative to transplantation, were tested by pyrosequencing at residues E119 and H275 (Table 1 ). The H275Y substitution alone, in proportions of 95-100%, was detected in the first four samples collected between day -64 and day -46; zanamivir treatment commenced on day -57. Five samples collected between day -39 and day -10 (the initial sample), had changes at residue E119, in addition to H275Y. Of note, the samples collected on day -25 and day -10 contained only 16% and 23% H275Y, respectively, while those collected on day -39, -32, and -18 had 100% H275Y. A mix of E119G and E119D variants (E119G/D) in addition to H275Y (100%) was detected in the sample from day -9, while that collected on day -3 had only E119G/D, and those collected on day +3 and day +17, respectively, had E119G/D with 34-37% H275Y. Two samples collected day +24 and day +34, respectively had E119G alone. The viral RNA titers varied and did not directly reflect the detection of E119D/G (Table 1) .
DISCUSSION
We report the emergence of an influenza A(H1N1)pdm09 virus infecting an immunocompromised infant after oseltamivir and zanamivir treatment, that carried the E119G substitution in the NA. This change confers highly reduced inhibition to zanamivir, peramivir and laninamivir. Moreover, a dual variant containing H275Y-E119G was detected and was highly resistant 
